Krakow, Poland – 03 September 2018 – Selvita will participate and present at the upcoming 25th Annual BioCentury NewsMakers in the Biotech Industry Conference, which is taking place on September 7, 2018, in New York, USA.
Pawel Przewiezlikowski, the CEO of Selvita, is scheduled to present a corporate overview at 8:30am ET on Friday, September 7, 2018, in the Room 301, at the Millennium Broadway Hotel & Conference Center in New York, with one-on-one meetings held throughout the day.
Selvita CEO will provide a corporate and scientific overview of the Company’s current activities, focusing on the most recent developments of its R&D oncology pipeline, strategic discovery collaborations and plans for the further corporate development.
A live webcast of the presentation can be accessed under the following link: media.rampard.com/newsmakers/selvita
NewsMakers presents only 48 companies which are handpicked to present their stories to institutional investors in the Biotech sector. Last year, more than 500 delegates congregated at NewsMakers, including money managers who controlled more than $600 billion in equity assets, with over $50 billion dedicated to healthcare and $15 billion dedicated to biotech.
To contact Selvita’s delegates at this conference, please contact us at: [email protected], or +48 539 939 584.
Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the USA (Greater Boston, San Francisco Bay), and in the UK (Cambridge). Selvita has currently several projects at early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).